基于个体当前与未来肺癌风险预测的筛查结果管理
该研究提出一种风险定制化肺癌筛查结果管理方法,将个体风险因素与低剂量CT图像特征纳入即时与下一次筛查(1年)肺癌检出风险计算,以推荐短期影像随访或1年/2年筛查间隔。研究扩展了LCRAT+CT个体化风险计算器,基于NLST中18,129例异常LDCT结果(即时检出肺癌649例,下次筛查检出235例)开发异常筛查部分,并评估该方法的潜在影响。
要点
- 应用NHS England草案方案可使76%参与者进入2年间隔,但延迟40%可检出癌症的诊断。
- LCRAT+CT阈值<0.95%累计风险同样使76%参与者进入2年间隔,仅延迟30%癌症诊断,较NHS方案减少25%。
- LCRAT+CT阈值<1.7%累计风险延迟40%癌症诊断,但使85%参与者进入2年间隔,较NHS方案进一步减少38%的1年筛查需求。
核心结论
- 使用个体化风险模型确定肺癌筛查管理可大幅减少筛查次数或增加早期检出。
研究设计与样本
- 研究扩展了LCRAT+CT个体化风险计算器,以预测阴性或异常LDCT筛查结果后的肺癌风险。
- 分析国家肺癌筛查试验(NLST)中18,129例异常LDCT结果,包括即时检出肺癌649例和下次筛查检出235例。
- 在NLST任何筛查结果(阴性或异常)的参与者中评估该方法的潜在影响。
主要发现
- 应用NHS England草案肺癌筛查方案,76%的NLST参与者被转至2年间隔,但40%的可检出癌症诊断被延迟。
- LCRAT+CT风险模型阈值<0.95%累计肺癌风险同样将76%参与者转至2年间隔,但仅延迟30%癌症诊断,较NHS方案减少25%。
- LCRAT+CT阈值<1.7%累计肺癌风险延迟40%癌症诊断,但将85%参与者转至2年间隔,较NHS方案进一步减少38%的1年筛查需求。
关键数值与推荐
- LCRAT+CT阈值<0.95%累计肺癌风险:76%参与者转至2年间隔,延迟30%癌症诊断。
- LCRAT+CT阈值<1.7%累计肺癌风险:85%参与者转至2年间隔,延迟40%癌症诊断。
- NHS England草案方案:76%参与者转至2年间隔,延迟40%癌症诊断。
临床怎么用
- 基于个体化风险模型(如LCRAT+CT)可辅助决定肺癌筛查异常或阴性结果后的随访间隔。
- 采用较低阈值(<0.95%)可在与NHS方案相同2年间隔转诊比例下减少癌症诊断延迟。
- 采用较高阈值(<1.7%)可在与NHS方案相同诊断延迟比例下减少1年筛查需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We propose a risk-tailored approach for management of lung cancer screening results. This approach incorporates individual risk factors and low-dose computed tomography (LDCT) image features into calculations of immediate and next-screen (1-y) risks of lung cancer detection, which in turn can recommend short-interval imaging or 1-year or 2-year screening intervals. METHODS: We first extended the "LCRAT+CT" individualized risk calculator to predict lung cancer risk after either a negative or abnormal LDCT screen result. To develop the abnormal screen portion, we analyzed 18,129 abnormal LDCT results in the National Lung Screening Trial (NLST), including lung cancers detected immediately (n = 649) or at the next screen (n = 235). We estimated the potential impact of this approach among NLST participants with any screen result (negative or abnormal). RESULTS: Applying the draft National Health Service (NHS) England protocol for lung screening to NLST participants referred 76% of participants to a 2-year interval, but delayed diagnosis for 40% of detectable cancers. The Lung Cancer Risk Assessment Tool+Computed Tomography (LCRAT+CT) risk model, with a threshold of less than 0.95% cumulative lung cancer risk, would also refer 76% of participants to a 2-year interval, but would delay diagnosis for only 30% of cancers, a 25% reduction versus the NHS protocol. Alternatively, LCRAT+CT, with a threshold of less than 1.7% cumulative lung cancer risk, would also delay diagnosis for 40% of cancers, but would refer 85% of participants for a 2-year interval, a 38% further reduction in the number of required 1-year screens beyond the NHS protocol. CONCLUSIONS: Using individualized risk models to determine management in lung cancer screening could substantially reduce the number of screens or increase early detection.
引用
- Robbins HA, Cheung LC, Chaturvedi AK, et al. Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks. J Thorac Oncol. 2021. PMID: 34648946. doi:10.1016/j.jtho.2021.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。